Suppression of Anti-Drug Antibodies to Infliximab or Adalimumab With the Addition of an Immunomodulator in Patients With Inflammatory Bowel Disease
Alimentary Pharmacology and Therapeutics - United Kingdom
doi 10.1111/apt.13994
Full Text
Open PDFAbstract
Available in full text
Date
February 23, 2017
Authors
Publisher
Wiley